Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Netherton Syndrome Treatment Market Size in the 7MM was ~USD 25 Million in 2022, is projected to increase ...

Researchers from Kumamoto University have identified a liver-derived protein, serine protease inhibitor A1 (SerpinA1), as a ...

Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical ...

Caseinolytic protease P (ClpP) is a conserved serine protease present in both bacteria and humans, essential for maintaining protein quality by degrading misfolded proteins.

Opaganib is under clinical development by RedHill Biopharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Groundbreaking 'Whole Body' Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface are ...

Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied ...

Disseminated intravascular coagulation (DIC) associated with hematologic malignancies, particularly acute promyelocytic leukemia (APL), is characterized by marked fibrinolytic activation, which leads ...

Third Quarter and Recent Clinical Developments Recent developments regarding narsoplimab, our lead monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (“MASP-2 ...